vs

Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Lemonade, Inc. (LMND). Click either name above to swap in a different company.

AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $228.1M, roughly 1.6× Lemonade, Inc.). AdvanSix Inc. runs the higher net margin — -0.8% vs -9.5%, a 8.7% gap on every dollar of revenue. On growth, Lemonade, Inc. posted the faster year-over-year revenue change (53.3% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-25.9M). Over the past eight quarters, Lemonade, Inc.'s revenue compounded faster (38.4% CAGR vs 3.4%).

AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.

Lemonade, Inc. is an American insurance company. The company offers renters' insurance, homeowners' insurance, car insurance, pet insurance, and term life insurance in the United States, as well as contents and liability policies in Germany and the Netherlands and renters' insurance in France. The company is based in New York City and has approximately 2.9 million customers. Lemonade does not hire human employees to process claims for customers, instead using artificial intelligence and chatb...

ASIX vs LMND — Head-to-Head

Bigger by revenue
ASIX
ASIX
1.6× larger
ASIX
$359.9M
$228.1M
LMND
Growing faster (revenue YoY)
LMND
LMND
+43.9% gap
LMND
53.3%
9.4%
ASIX
Higher net margin
ASIX
ASIX
8.7% more per $
ASIX
-0.8%
-9.5%
LMND
More free cash flow
ASIX
ASIX
$62.0M more FCF
ASIX
$36.1M
$-25.9M
LMND
Faster 2-yr revenue CAGR
LMND
LMND
Annualised
LMND
38.4%
3.4%
ASIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASIX
ASIX
LMND
LMND
Revenue
$359.9M
$228.1M
Net Profit
$-2.8M
$-21.7M
Gross Margin
7.6%
Operating Margin
-0.7%
-9.0%
Net Margin
-0.8%
-9.5%
Revenue YoY
9.4%
53.3%
Net Profit YoY
-892.9%
27.7%
EPS (diluted)
$-0.11
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASIX
ASIX
LMND
LMND
Q4 25
$359.9M
$228.1M
Q3 25
$374.5M
$194.5M
Q2 25
$410.0M
$164.1M
Q1 25
$377.8M
$151.2M
Q4 24
$329.1M
$148.8M
Q3 24
$398.2M
$136.6M
Q2 24
$453.5M
$122.0M
Q1 24
$336.8M
$119.1M
Net Profit
ASIX
ASIX
LMND
LMND
Q4 25
$-2.8M
$-21.7M
Q3 25
$-2.6M
$-37.5M
Q2 25
$31.4M
$-43.9M
Q1 25
$23.3M
$-62.4M
Q4 24
$352.0K
$-30.0M
Q3 24
$22.3M
$-67.7M
Q2 24
$38.9M
$-57.2M
Q1 24
$-17.4M
$-47.3M
Gross Margin
ASIX
ASIX
LMND
LMND
Q4 25
7.6%
Q3 25
6.8%
Q2 25
14.3%
Q1 25
14.2%
Q4 24
3.4%
Q3 24
14.4%
Q2 24
17.9%
Q1 24
0.9%
Operating Margin
ASIX
ASIX
LMND
LMND
Q4 25
-0.7%
-9.0%
Q3 25
-0.9%
-18.7%
Q2 25
7.7%
-26.0%
Q1 25
7.7%
-40.6%
Q4 24
-3.9%
-25.4%
Q3 24
7.5%
-48.2%
Q2 24
11.5%
-45.2%
Q1 24
-7.0%
-38.0%
Net Margin
ASIX
ASIX
LMND
LMND
Q4 25
-0.8%
-9.5%
Q3 25
-0.7%
-19.3%
Q2 25
7.7%
-26.8%
Q1 25
6.2%
-41.3%
Q4 24
0.1%
-20.2%
Q3 24
5.6%
-49.6%
Q2 24
8.6%
-46.9%
Q1 24
-5.2%
-39.7%
EPS (diluted)
ASIX
ASIX
LMND
LMND
Q4 25
$-0.11
$-0.27
Q3 25
$-0.10
$-0.51
Q2 25
$1.15
$-0.60
Q1 25
$0.86
$-0.86
Q4 24
$0.02
$-0.42
Q3 24
$0.82
$-0.95
Q2 24
$1.43
$-0.81
Q1 24
$-0.65
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASIX
ASIX
LMND
LMND
Cash + ST InvestmentsLiquidity on hand
$19.8M
$399.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$815.2M
$533.6M
Total Assets
$1.7B
$1.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASIX
ASIX
LMND
LMND
Q4 25
$19.8M
$399.1M
Q3 25
$23.7M
$369.4M
Q2 25
$18.4M
$398.8M
Q1 25
$8.3M
$329.7M
Q4 24
$19.6M
$403.5M
Q3 24
$17.3M
$360.9M
Q2 24
$12.1M
$387.2M
Q1 24
$20.6M
$300.8M
Stockholders' Equity
ASIX
ASIX
LMND
LMND
Q4 25
$815.2M
$533.6M
Q3 25
$818.2M
$516.2M
Q2 25
$823.7M
$527.1M
Q1 25
$794.4M
$545.5M
Q4 24
$774.6M
$593.4M
Q3 24
$766.4M
$593.0M
Q2 24
$746.6M
$635.2M
Q1 24
$713.2M
$676.4M
Total Assets
ASIX
ASIX
LMND
LMND
Q4 25
$1.7B
$1.9B
Q3 25
$1.7B
$1.9B
Q2 25
$1.6B
$1.9B
Q1 25
$1.6B
$1.9B
Q4 24
$1.6B
$1.8B
Q3 24
$1.5B
$1.8B
Q2 24
$1.5B
$1.7B
Q1 24
$1.5B
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASIX
ASIX
LMND
LMND
Operating Cash FlowLast quarter
$63.7M
$-16.5M
Free Cash FlowOCF − Capex
$36.1M
$-25.9M
FCF MarginFCF / Revenue
10.0%
-11.4%
Capex IntensityCapex / Revenue
7.7%
4.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$6.4M
$-69.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASIX
ASIX
LMND
LMND
Q4 25
$63.7M
$-16.5M
Q3 25
$26.6M
$4.5M
Q2 25
$21.1M
$5.5M
Q1 25
$11.4M
$-47.2M
Q4 24
$64.2M
$-11.4M
Q3 24
$57.3M
$16.3M
Q2 24
$50.2M
$-11.7M
Q1 24
$-36.2M
$-29.8M
Free Cash Flow
ASIX
ASIX
LMND
LMND
Q4 25
$36.1M
$-25.9M
Q3 25
$66.0K
$2.6M
Q2 25
$-7.2M
$3.4M
Q1 25
$-22.6M
$-49.5M
Q4 24
$29.8M
$-20.8M
Q3 24
$26.8M
$14.1M
Q2 24
$16.7M
$-13.2M
Q1 24
$-71.6M
$-32.3M
FCF Margin
ASIX
ASIX
LMND
LMND
Q4 25
10.0%
-11.4%
Q3 25
0.0%
1.3%
Q2 25
-1.7%
2.1%
Q1 25
-6.0%
-32.7%
Q4 24
9.1%
-14.0%
Q3 24
6.7%
10.3%
Q2 24
3.7%
-10.8%
Q1 24
-21.3%
-27.1%
Capex Intensity
ASIX
ASIX
LMND
LMND
Q4 25
7.7%
4.1%
Q3 25
7.1%
1.0%
Q2 25
6.9%
1.3%
Q1 25
9.0%
1.5%
Q4 24
10.4%
6.3%
Q3 24
7.7%
1.6%
Q2 24
7.4%
1.2%
Q1 24
10.5%
2.1%
Cash Conversion
ASIX
ASIX
LMND
LMND
Q4 25
Q3 25
Q2 25
0.67×
Q1 25
0.49×
Q4 24
182.29×
Q3 24
2.57×
Q2 24
1.29×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASIX
ASIX

Plant Nutrients$140.0M39%
Chemical Intermediates$92.8M26%
Caprolactam$64.4M18%
Nylon Resins$62.8M17%

LMND
LMND

Segment breakdown not available.

Related Comparisons